Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, and Tropicamide, the active ingredients in Mydrane, are a local anesthetic; an alpha‑1 adrenergic agonist; and an anticholinergic, presented as a sterile solution for intracameral injection use. It provides intra‑operative pupil dilation and anesthesia during cataract and other intra‑ocular surgeries in adult patients.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmic surgery centres, clinics, and research institutions worldwide.

Mydrane is employed in ophthalmic procedures to achieve pupil dilation and intra‑ocular anesthesia.

Cataract surgery: provides rapid pupil dilation and corneal anesthesia to facilitate lens removal. Other intra‑ocular surgeries (e.g., glaucoma, vitreoretinal procedures): ensures adequate mydriasis and analgesia during the operation. Intra‑operative pupil management: maintains a stable, dilated pupil throughout the procedure.

Mydrane may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient ocular pain or discomfort. - Mild conjunctival redness. - Temporary blurred vision. - Slight increase in intra‑ocular pressure. - Mild headache. - Nausea.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Sustained elevation of intra‑ocular pressure requiring intervention. - Persistent mydriasis leading to photophobia. - Corneal edema or endothelial damage. - Retinal toxicity (rare). - Systemic cardiovascular effects such as hypertension or arrhythmia.

When using Mydrane, clinicians should observe the following precautions.

Allergy assessment: verify no known hypersensitivity to lidocaine, phenylephrine, or tropicamide. Intra‑ocular pressure monitoring: measure IOP before and after injection, especially in glaucoma patients. Systemic cardiovascular status: avoid in patients with uncontrolled hypertension or significant arrhythmias. Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. Drug interactions: review concomitant ocular vasoconstrictors or cholinergic agents. Store at ambient temperature: keep in the original container, protect from light and moisture.

Mydrane may interact with other medications; awareness of the interaction level is important.

Major Interactions (Avoid): - Systemic phenylephrine‑containing products: additive hypertensive effects. - Other topical ocular vasoconstrictors: risk of excessive pupil constriction reversal. - Beta‑blocker eye drops: may blunt cardiovascular response to phenylephrine.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): may enhance cycloplegic effect. - Additional topical anesthetics: may increase local anesthetic load. - MAO inhibitors: potential for hypertensive crisis when combined with phenylephrine.